Chiba-Based GeneFrontier Enters Drug Discovery Field
This article was originally published in PharmAsia News
Executive Summary
Chiba-based biopharmaceutical company GeneFrontier announced it will utilize antibody technology and enter the drug discovery business. The company plans to obtain proteins that were discovered by university research centers and will make antibodies based on the proteins, then license the protein and antibody set products to pharmaceutical companies. Currently, the company has one such project under way, and plans to license it to drug companies within the year. The company aims to conduct four projects and commercialize one to two products annually. (Click here for more - Japanese language